Starpharma ROCE
Quel est le ROCE de Starpharma?
Le ROCE de Starpharma Holdings Limited est 0.00%
Quelle est la définition de ROCE?
Le retour sur capital utilisé (ROCE) est un ratio financier qui mesure la rentabilité d'une entreprise et l'efficacité avec laquelle son capital est utilisé.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE des entreprises dans Health Care secteur sur ASX par rapport à Starpharma
Que fait Starpharma?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Entreprises avec roce similaire à Starpharma
- Omega Alpha Spac a ROCE de -0.01%
- The Gap a ROCE de -0.01%
- Elemental Royalties Ltd a ROCE de -0.01%
- Auburn National Bancorp a ROCE de -0.01%
- Galaxy Digital a ROCE de -0.01%
- The Gap a ROCE de -0.01%
- Starpharma a ROCE de 0.00%
- Tejon Ranch Co a ROCE de 0.01%
- Glen Burnie Bancorp a ROCE de 0.02%
- MSP Steel & Power a ROCE de 0.02%
- TTL Beteiligungs- und Grundbesitz-AG a ROCE de 0.03%
- First Foundation Inc a ROCE de 0.03%
- FirstMark Horizon Acquisition a ROCE de 0.03%